NFGH
LBRX

Nan Fung Group Holdings’s LB Pharmaceuticals LBRX Stock Holding History

Nan Fung Group Holdings’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.6M Buy
630,657
+330,657
+110% +$7.63M 12.82% 3
2025
Q4 		$6.68M Hold
300,000
– – 5.98% 5
2025
Q3 		$4.74M Buy
+300,000
New +$4.76M 7.95% 6

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Nan Fung Group Holdings's LBRX Position: Q1 2026 in Review

Nan Fung Group Holdings increased its LB Pharmaceuticals (LBRX) stake by 110% in Q1 2026, buying an estimated $7.63M and bringing the position to 630,657 shares worth $15.6M. The position accounts for 12.82% of the portfolio, ranked #3.

Nan Fung Group Holdings first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Nan Fung Group Holdings held 630,657 shares of LB Pharmaceuticals worth $15.6M as of Q1 2026.
  • Nan Fung Group Holdings bought 330,657 LB Pharmaceuticals shares in Q1 2026, an estimated $7.63M.
  • LB Pharmaceuticals made up 12.82% of Nan Fung Group Holdings's portfolio in Q1 2026, its #3 holding.
  • Nan Fung Group Holdings first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Nan Fung Group Holdings's 13F filing for Q1 2026, filed 14 May 2026.